Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Change in Inventory (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Change in Inventory for 9 consecutive years, with $70.5 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory fell 11.18% to $70.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.2 million through Dec 2025, up 1.83% year-over-year, with the annual reading at $93.2 million for FY2025, 1.83% up from the prior year.
  • Change in Inventory for Q4 2025 was $70.5 million at BeOne Medicines, up from $28.8 million in the prior quarter.
  • The five-year high for Change in Inventory was $91.6 million in Q4 2021, with the low at -$23.8 million in Q3 2024.
  • Average Change in Inventory over 5 years is $26.8 million, with a median of $28.7 million recorded in 2022.
  • Peak annual rise in Change in Inventory hit 1357.53% in 2021, while the deepest fall reached 7450.9% in 2021.
  • Over 5 years, Change in Inventory stood at $91.6 million in 2021, then plummeted by 120.67% to -$18.9 million in 2022, then skyrocketed by 567.6% to $88.6 million in 2023, then fell by 10.38% to $79.4 million in 2024, then decreased by 11.18% to $70.5 million in 2025.
  • According to Business Quant data, Change in Inventory over the past three periods came in at $70.5 million, $28.8 million, and -$2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.